In the last decade, advances in understanding the neurobiology of Alzheimer's disease (AD)
have translated into an increase in clinical trials assessing various potential AD treatments …

Pathological, genetic, biochemical and pharmacological studies support the hypothesis that
brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimer's …

Drugs currently used for the treatment of Alzheimer's disease (AD) produce limited clinical
benefits, and there is no diseasemodifying therapy yet available. Compounds that inhibit or …

Drugs currently used to treat Alzheimer's Disease (AD) have limited therapeutic value and
do not affect the main neuropathological hallmarks of the disease, ie, senile plaques and …

There has been a lot of disappointment surrounding the recent failure of the largest ever
study in patients with Alzheimer's disease (AD) with tarenflurbil, a compound believed to …

Alzheimer's disease (AD) is the most common form of dementia in the elderly and its
prevalence is set to increase rapidly in coming decades. However, there are as yet no …

Alzheimer's disease is a form of sporadic, age-related dementia. According to the “amyloid
hypothesis”, the processing of β-amyloid precursor protein (APP) leads to the formation of …

Alzheimer's disease (AD) is the most common cause of dementia among older people, and
the prevalence of this disease is estimated to rise quickly in the upcoming years …

Pathological, genetic, biochemical and pharmacological studies support the hypothesis that
brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimer's …

Currently, there are no disease-modifying therapies available for Alzheimer's disease (AD).
Acetylcholinesterase inhibitors and memantine are licensed for AD and have moderate …